Navigation Links
TGen-led study reveals TWEAK-Fn14 as key drug target
Date:11/8/2013

PHOENIX, Ariz. Nov. 8, 2013 A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute (TGen).

TWEAK is a cytokine, or soluble protein, that controls many cellular activities and acts by binding to a cell surface receptor known as Fn14. TWEAK binding to Fn14 triggers a wide range of cellular activities, including blood clotting, inflammation, cell proliferation, cell migration, and the creation of new blood vessels.

While many of these activities are beneficial for example, helping to heal a cut excessive TWEAK-Fn14 activation also has been linked to tissue damage and degradation, including autoimmune diseases, as well as the survival, migration and invasion of cancer cells.

"Our results show that the TWEAK-Fn14 interaction is a viable drug target, and they provide the foundation for further exploration of this system in researching invasive cancers," said Dr. Nhan Tran, an Associate Professor in TGen's Cancer and Cell Biology Division.

"Because of its unique qualities and association with acute injuries, this drug-like molecule not only could benefit cancer patients, but also might be applied to patients with autoimmunity, heart disease like atherosclerosis, and rheumatoid arthritis," said Dr. Tran, the study's senior author.

The study Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-Inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis publishes in today's (Nov. 8) issue of The Journal of Biological Chemistry.

Overexpression of TWEAK-Fn14 has been linked to several types of cancer, including breast, pancreatic, esophageal, lung, liver and most important in this study glioblastoma.

By using protein-protein docking models, 129 small molecules were selected for screening, which identified four that inhibited the binding of TWEAK to Fn14.

One compound in particular, L524-0366, "completely suppressed TWEAK induced glioma cell migration without any potential cytotoxic effects," the study concluded.

"These results represent a significant step towards proving that the TWEAK-Fn14 interaction may be key to treating invasive glioblastoma brain tumors," said Dr. Michael Berens, TGen Deputy Director for Research Resources and Director of TGen's Cancer and Cell Biology Division.

"The next step will be to move this compound forward for drug development and eventual testing in clinical trials, where it might bring immediate benefit for patients," said Dr. Berens, a co-author of the study.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen-led study identifies genes associated with unhealthy liver function
2. Study using stem cells to improve organ transplantation to receive $12 million
3. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
4. Study finds that Americans want doctors guidance on genetic test results
5. New study assesses injuries seen in the emergency department to children of teenage parents
6. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
7. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
8. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
9. Physician shortage could be cut by new primary care models, study finds
10. Study: Access to health care increases prescription opioid availability and associated abuse
11. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... , ... Expanding its commitment to the welfare of children through its new ... for Caterina’s Club during its annual West Coast gala - Notte di Savoia ... donated for the Southern California-based charity from funds raised by the event. The grant ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited to present ... Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s oral presentation ... both the Basic Science Award for Oral Presentation and the Fertility Society of Australia ...
(Date:6/18/2019)... ... June 18, 2019 , ... Cosmetic Town, an online ... of cosmetic facial rejuvenation in June. The Cosmetic Town website will showcase cosmetic ... performing various methods of cosmetic facial rejuvenation and videos that take viewers behind ...
(Date:6/18/2019)... PLEASANTON, Calif. (PRWEB) , ... June 18, 2019 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Aaron ...
(Date:6/16/2019)... Calif. (PRWEB) , ... June 14, 2019 , ... ... / Cyber Security solutions, today announced it has received the coveted “2019 ... award winning DLP that Works Platform along with the latest additions to its ...
Breaking Medicine News(10 mins):
(Date:6/14/2019)... ... June 14, 2019 , ... ... a forecasting and analytics platform that helps Life Sciences Manufacturers accurately project ... for Life Sciences business leaders: accurate, automated forecasting of rebates and discounts ...
(Date:6/13/2019)... ... June 13, 2019 , ... Alliance Cost Containment, LLC (ACC) ... the healthcare space. The $5.8M in savings is in addition to $17.6M saved over ... , With an acquisition in Q4 2019, the client increased their Fortune 500 status ...
(Date:6/13/2019)... Va. (PRWEB) , ... June 13, 2019 , ... The ... new executive director to succeed current executive director Nicholas Croce Jr., MS. The search ... of the Board of Directors, past APNA Presidents, and Council and Chapter leaders. , ...
Breaking Medicine Technology: